Form 4: Astria Therapeutics CMO Cashes In Options Post-Merger

Astria Therapeutics' Chief Medical Officer, Christopher Morabito, received cash for his in-the-money stock options following the company's merger with BioCryst Pharmaceuticals.

Summary

• Christopher Morabito, Chief Medical Officer of Astria Therapeutics, Inc. (ATXS), reported changes in his beneficial ownership of securities.
• The changes occurred on January 23, 2026, as a result of a merger between Astria Therapeutics, Inc. and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Astria Therapeutics, Inc. survived the merger and became a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• In-the-money stock options (exercise price less than $13.00) held by Mr. Morabito became fully vested and exercisable, then were canceled in exchange for a cash payment.
• The cash payment for each in-the-money option was calculated as the total number of shares subject to the option multiplied by the difference between $13.00 and the option's exercise price.
• Mr. Morabito held two in-the-money stock options: one for 80,000 shares with an exercise price of $3.87, and another for 262,500 shares with an exercise price of $6.41.
• Out-of-the-money stock options (exercise price equal to or greater than $13.00) were canceled for no consideration and are not reported in this filing.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person, Christopher Morabito, who realized a substantial cash gain from his stock options due to the merger. For Astria Therapeutics as an independent entity, the sentiment is neutral as the filing reports a completed acquisition, marking the end of its independent public trading status.

Positives

• Christopher Morabito received a significant cash payout totaling $2,460,275 for his in-the-money stock options as a result of the merger.
• The first option for 80,000 shares at an exercise price of $3.87 yielded $730,400 (80,000 * ($13.00 $3.87)).
• The second option for 262,500 shares at an exercise price of $6.41 yielded $1,729,875 (262,500 * ($13.00 $6.41)).

Negatives

• Any stock options with an exercise price equal to or greater than $13.00 (out-of-the-money options) were canceled for no consideration, resulting in a loss for holders of such options.
• Astria Therapeutics, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.

Risks

• Holders of out-of-the-money stock options (exercise price equal to or greater than $13.00) faced the risk of their options being canceled for no consideration, which was realized in this merger.

Future Outlook

This Form 4 reports a completed transaction and does not provide forward-looking statements or guidance regarding the future operations or financial performance of the merged entity.

Management Comments

• "Pursuant to an Agreement and Plan of Merger, dated as of October 14, 2025, by and among the Issuer, BioCryst Pharmaceuticals, Inc. ('BioCryst'), and Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst, on January 23, 2026, Axel Merger Sub, Inc. merged with and into the Issuer, with the Issuer surviving and becoming a wholly-owned subsidiary of BioCryst (the 'Merger')."
• "At the effective time of the Merger (the 'Effective Time'), each Issuer stock option for which the applicable exercise price was less than $13.00 (each, an 'In-the-Money Option') that was outstanding immediately prior to the Effective Time became fully vested and exercisable and was canceled in exchange for the payment in cash equal to the product of (i) the total number of shares of common stock subject to such canceled In-the-Money Option immediately prior to the Effective Time and (ii) the excess of $13.00 over the exercise price per share subject to each such canceled In-the-Money Option, without interest."
• "At the Effective Time, each Issuer stock option for which the applicable exercise price was equal to or greater than $13.00 (each, an 'Out-of-the-Money Option') that was outstanding immediately prior to the Effective Time was canceled for no consideration, which cancelation is exempt from Section 16 of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16a-4(d) and Rule 16b-6(d) thereunder. Accordingly, the Reporting Person's Out-of-the-Money Options that were canceled in the Merger are not reported herein."

Industry Context

This filing reflects a consolidation event within the biopharmaceutical industry, where a smaller entity (Astria Therapeutics) was acquired by a larger player (BioCryst Pharmaceuticals). Such mergers are common strategies for larger companies to expand their pipeline or market share, and for smaller companies to gain resources or an exit for shareholders.

Comparison to Industry Standards

• The treatment of stock options in a merger, where in-the-money options are cashed out and out-of-the-money options are canceled, is a standard practice in corporate acquisitions, aligning with typical merger agreements in the biopharmaceutical sector.
• The $13.00 per share consideration for options is specific to this transaction and would need to be compared against the pre-merger trading price of Astria Therapeutics (ATXS) and other recent biopharma acquisitions to assess its fairness to option holders and shareholders, though this filing does not provide such comparative data.

Management Changes

Corporate Governance

Related Party Transactions

• The cancellation and cash settlement of stock options for Christopher Morabito, an officer of Astria Therapeutics, Inc., as part of the merger with BioCryst Pharmaceuticals, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders of Astria Therapeutics, Inc. would have received consideration for their shares as per the merger agreement, though the details are not in this Form 4.
• Option holders, such as Christopher Morabito, received cash for in-the-money options but lost any value from out-of-the-money options.
• Employees of Astria Therapeutics, Inc. are now part of a larger organization under BioCryst Pharmaceuticals, Inc., which may impact their roles, benefits, and corporate culture.

Next Steps

• The merger has been completed, and Astria Therapeutics, Inc. is now a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc. No further specific next steps for the former public entity are detailed in this filing.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Stock Options, Form 4, Insider Transaction, Beneficial Ownership, Christopher Morabito, Chief Medical Officer